Ocumetics Technology Corp.
OTC.V
Toronto Stock Exchange Ventures0.45
CAD
-0.02
- -
Ocumetics Technology Corp.
OTC.V
(Toronto Stock Exchange Ventures)
Recent
price
0.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ocumetics Technology Corp. (TSXV: OTC) is a Canada-based research and product development company specializing in adaptive lens designs for the ophthalmic industry. The company focuses on developing the Ocumetics Bionic Lens, an expandable accommodating intraocular lens that fits within the natural lens compartment of the eye, primarily targeting individuals over 45 years of age suffering from presbyopia, cataracts, or other age-related vision deterioration; it leverages the eye's natural ciliary muscle activity and zonules to enable seamless focus shifting from distance to near vision without the need for eyeglasses, contact lenses, or corrective surgery lag time. The proprietary lens design incorporates self-adapting suspension systems with cushions that conform to individual eye parameters, serving as a replaceable docking station for customized optics and future nanotechnologies. Founded in 2012 by Dr. Garth Webb, chief scientific officer, and headquartered at 1250, 639 - 5th Avenue S.W., Calgary, Alberta, Canada, Ocumetics operates in the preclinical and early clinical stages of its core technology, with ongoing research emphasizing safety, efficacy, and mass production feasibility for global patient care. The company conducts clinical studies, including surgical evaluations in Mexico City, reporting continued vision improvements in initial patient groups and surpassing early expectations in visual acuity outcomes. In the past two years, Ocumetics has advanced its first-in-human clinical trials, completing multiple surgical days and releasing positive interim data on patient vision recovery as part of its ongoing Mexico City study. The company announced a C$2.5 million brokered LIFE private placement in November 2025, led by Centurion One Capital Corp. as sole bookrunner, through the sale of up to 3.47 million units at C$0.72 each, with proceeds allocated to fund clinical trials, research and development, and general corporate purposes; an over-allotment option could raise an additional C$375,000. Previously known as Quantum Blockchain Technologies Ltd., Ocumetics rebranded in August 2021 to reflect its strategic shift to vision enhancement technologies.